L
Laura Obici
Researcher at University of Pavia
Publications - 233
Citations - 12821
Laura Obici is an academic researcher from University of Pavia. The author has contributed to research in topics: Amyloidosis & Transthyretin. The author has an hindex of 58, co-authored 208 publications receiving 10538 citations. Previous affiliations of Laura Obici include Radboud University Nijmegen & University of Birmingham.
Papers
More filters
Journal ArticleDOI
Systemic Cardiac Amyloidoses Disease Profiles and Clinical Courses of the 3 Main Types
Claudio Rapezzi,Giampaolo Merlini,Candida Cristina Quarta,Letizia Riva,Simone Longhi,Ornella Leone,Fabrizio Salvi,Paolo Ciliberti,Francesca Pastorelli,Elena Biagini,Fabio Coccolo,Robin M. T. Cooke,Letizia Bacchi-Reggiani,Diego Sangiorgi,Alessandra Ferlini,Michele Cavo,Elena Zamagni,Maria Luisa Fonte,Giovanni Palladini,Francesco Salinaro,Francesco Musca,Laura Obici,Angelo Branzi,Stefano Perlini +23 more
TL;DR: AL, ATTRm, and ATTRwt should be considered 3 different cardiac diseases, probably characterized by different pathophysiological substrates and courses.
Journal ArticleDOI
Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial
John L. Berk,Ole B. Suhr,Laura Obici,Yoshiki Sekijima,Steven R. Zeldenrust,Taro Yamashita,Michael A. Heneghan,Peter D. Gorevic,William J. Litchy,Janice F. Wiesman,Erik Nordh,Manuel Corato,Alessandro Lozza,Andrea Cortese,Jessica Robinson-Papp,Theodore Colton,Denis Rybin,Alice Bisbee,Yukio Ando,Shu-ichi Ikeda,David C. Seldin,Giampaolo Merlini,Martha Skinner,Jeffery W. Kelly,Peter J. Dyck +24 more
TL;DR: Among patients with familial amyloid polyneuropathy, the use of diflunisal compared with placebo for 2 years reduced the rate of progression of neurological impairment and preserved quality of life.
Journal ArticleDOI
Guideline of transthyretin-related hereditary amyloidosis for clinicians
Yukio Ando,Teresa Coelho,John L. Berk,Márcia Waddington Cruz,Bo Göran Ericzon,Shu-ichi Ikeda,W. David Lewis,Laura Obici,Violaine Planté-Bordeneuve,Claudio Rapezzi,Gérard Said,Fabrizio Salvi +11 more
TL;DR: Providing guidance on making a definitive diagnosis, methods for disease staging and evaluation of disease progression, and discuss symptom mitigation and treatment strategies, including liver transplant and several pharmacotherapies that have shown promise in clinical trials are provided.
Journal ArticleDOI
Serum N-Terminal Pro–Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis
Giovanni Palladini,Carlo Campana,Catherine Klersy,Alessandra Balduini,Giovanbattista Vadacca,Vittorio Perfetti,Stefano Perlini,Laura Obici,Edoardo Ascari,Gianvico Melzi d'Eril,Remigio Moratti,Giampaolo Merlini +11 more
TL;DR: NT-proBNP appeared to be the most sensitive index of myocardial dysfunction and the most powerful prognostic determinant in AL amyloidosis and can be useful in designing therapeutic strategies and monitoring response.
Journal ArticleDOI
Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.
Giovanni Palladini,Vittorio Perfetti,Laura Obici,Riccardo Caccialanza,Alessandra Semino,Fausto Adami,Giobatta Cavallero,Roberto Rustichelli,Giovambattista Virga,Giampaolo Merlini +9 more
TL;DR: M-Dex represents a feasible and effective therapeutic option for patients with advanced AL who are ineligible for ASCT and functional improvement of the organs involved was observed.